RG
RIGL icon

Redmile Group’s Rigel Pharmaceuticals RIGL Stock Holding History

Redmile Group’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-74,458
Closed -$2.61M – 95
2020
Q4 		$2.61M Hold
74,458
– – 0.03% 82
2020
Q3 		$1.79M Buy
+74,458
New +$1.83M 0.03% 76

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Redmile Group's RIGL Position: Q1 2021 in Review

Redmile Group sold out of Rigel Pharmaceuticals (RIGL) in Q1 2021, closing a stake of 74,458 shares — an estimated $2.61M sold.

Redmile Group first reported a position in RIGL in Q3 2020 and held it in 2 quarters. The position peaked at $2.61M in Q4 2020. 152 funds tracked by Wall St. Rank hold RIGL as of Q1 2021.

  • Redmile Group reported no remaining Rigel Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Redmile Group sold 74,458 Rigel Pharmaceuticals shares in Q1 2021, an estimated $2.61M.
  • Redmile Group first reported a position in Rigel Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Redmile Group's Rigel Pharmaceuticals position peaked at $2.61M in Q4 2020.
  • 152 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2021.

Based on Redmile Group's 13F filing for Q1 2021, filed 17 May 2021.